Literature DB >> 12049856

The UK blood transfusion service: over a (patent) barrel?

P Simmonds1, J Kurtz, R S Tedder.   

Abstract

Mesh:

Substances:

Year:  2002        PMID: 12049856     DOI: 10.1016/s0140-6736(02)08663-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  Comparison of monolisa HCV Ag/Ab ULTRA with two anti-HCV assays for the detection of HCV infection in hospital setting.

Authors:  Server Yagci; Elizaveta Padalko
Journal:  Curr Microbiol       Date:  2011-11-11       Impact factor: 2.188

Review 2.  The rationale for pathogen-inactivation treatment of blood components.

Authors:  John A J Barbara
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

3.  Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection.

Authors:  Syria Laperche; Nadine Le Marrec; Annie Girault; Françoise Bouchardeau; Annabelle Servant-Delmas; Michèle Maniez-Montreuil; Pierre Gallian; Thierry Levayer; Pascal Morel; Nicole Simon
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

4.  Globalization and blood safety.

Authors:  A Farrugia
Journal:  ISBT Sci Ser       Date:  2006-08-15

5.  Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States.

Authors:  Christopher E Bell; Marc F Botteman; Xin Gao; Joel L Weissfeld; Maarten J Postma; Chris L Pashos; Darrell Triulzi; Ulf Staginnus
Journal:  Clin Ther       Date:  2003-09       Impact factor: 3.393

6.  Hepatitis C virus core antigen assay: can we think beyond convention in resource limited settings?

Authors:  Anita Chakravarti; Mayank S Chauhan; Gaurav Dogra; Sayantan Banerjee
Journal:  Braz J Infect Dis       Date:  2013-04-18       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.